Pacific Biosciences of California (PACB) Stock Analysis & AI Equity Report

Medical - Devices USD Explore free reports

Pacific Biosciences of California (PACB) overview

Pacific Biosciences of California (PACB) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 160m and operating profit of USD -554m; the year-end share price was 1.87 USD and market capitalisation was USD 565m. Pacific Biosciences of California is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Pacific Biosciences of California's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 5.3mFY 2025
Share price1.87 USDFY 2025 year end
RevenueUSD 160mFY 2025
Operating profitUSD -554mFY 2025
Net earningsUSD -546mFY 2025
Market capitalisationUSD 565mFY 2025 year end

About Pacific Biosciences of California

Pacific Biosciences designs, develops, and manufactures sequencing systems and related products for genomic research. Its HiFi long-read technology supports studies of genomes, transcriptomes, and epigenomes across applications including human genetics, agriculture, infectious disease, microbiology, and oncology. Customers include research institutions, laboratories, genome centers, hospitals, clinical research organizations, pharmaceutical companies, and agricultural companies.

Generate the Pacific Biosciences of California report

Pacific Biosciences of California is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Pacific Biosciences of California and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Pacific Biosciences of California

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.